2024
Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy.
Ali M, Eid M, Saliby R, Choi S, McKay R, Siva S, Braun D, Chen Y. Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy. American Society Of Clinical Oncology Educational Book 2024, 44: e438658. PMID: 38875505, DOI: 10.1200/edbk_438658.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaTreatment sequencing strategiesCell carcinomaImmune checkpoint inhibitors targeting PD-1Chimeric antigen receptor T-cell therapyCheckpoint inhibitors targeting PD-1Management of renal cell carcinomaAdvanced renal cell carcinomaProstate-specific membrane antigenLandscape of renal cell carcinomaRCC-associated antigensImmune checkpoint inhibitionT-cell therapyPrimary kidney tumorsAssess treatment responseChanging treatment landscapeCarbonic anhydrase IXFunctional imagingFunctional imaging modalitiesCheckpoint inhibitionPD-1Immunotherapy strategiesLAG-3Membrane antigenT cellsImpact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes
Saliby R, Labaki C, Jammihal T, Xie W, Sun M, Shah V, Saad E, Kane M, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer R, Powles T, Rini B, Albiges L, Pal S, McGregor B, McKay R, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 2024, 42: 732-735. PMID: 38579722, PMCID: PMC11130783, DOI: 10.1016/j.ccell.2024.03.002.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellHumansImmune Checkpoint InhibitorsImmunotherapyKidney NeoplasmsMachine LearningMolecular Targeted TherapyTreatment Outcome
2023
Immunobiology and Metabolic Pathways of Renal Cell Carcinoma
Braun D, Chakraborty A. Immunobiology and Metabolic Pathways of Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 827-840. PMID: 37246090, DOI: 10.1016/j.hoc.2023.04.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsCarcinoma, Renal CellHumansImmune Checkpoint InhibitorsKidney NeoplasmsMetabolic Networks and PathwaysConceptsRenal cell carcinomaCell carcinomaAdvanced renal cell carcinomaClear cell renal cell carcinomaImmune checkpoint inhibitorsCell renal cell carcinomaNew treatment targetsFuture clinical developmentCheckpoint inhibitorsNovel therapeutic developmentDurable responsesMost patientsMetabolic dysregulationDistinct tumorsClinical developmentImmune pathwaysTreatment targetsTherapeutic developmentCarcinomaCurrent understandingMetabolic pathwaysPatientsImmunobiologyTumorsPathway
2022
Germline variants associated with toxicity to immune checkpoint blockade
Groha S, Alaiwi S, Xu W, Naranbhai V, Nassar A, Bakouny Z, El Zarif T, Saliby R, Wan G, Rajeh A, Adib E, Nuzzo P, Schmidt A, Labaki C, Ricciuti B, Alessi J, Braun D, Shukla S, Keenan T, Van Allen E, Awad M, Manos M, Rahma O, Zubiri L, Villani A, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl K, Freedman M, Choueiri T, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nature Medicine 2022, 28: 2584-2591. PMID: 36526723, PMCID: PMC10958775, DOI: 10.1038/s41591-022-02094-6.Peer-Reviewed Original ResearchMeSH KeywordsCognitionGenome-Wide Association StudyGerm CellsImmune Checkpoint InhibitorsInterleukin-7Retrospective StudiesConceptsImmune-related adverse eventsImmune checkpoint inhibitorsGrade immune-related adverse eventsGermline variantsICI initiationCheckpoint inhibitorsAdverse eventsCheckpoint blockadeImproved survivalDiscovery cohortLymphocyte homeostasisSignificant associationCancer typesIL7Remarkable responsePatientsCritical regulatorGenome-wide significant associationAssociationWide association studyIndependent studiesAssociation studiesBlockadeCohortVariants
2021
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology 2021, 18: 199-214. PMID: 33437048, PMCID: PMC8317018, DOI: 10.1038/s41571-020-00455-z.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellDrugs, InvestigationalHumansImmune Checkpoint InhibitorsImmunologic FactorsImmunotherapyKidney NeoplasmsTherapies, InvestigationalConceptsRenal cell carcinomaImmune checkpoint inhibitorsCell carcinomaAdvanced stage renal cell carcinomaContext of RCCNovel immune-based therapiesAntigen-directed therapiesImmunotherapy-based combinationsSuccess of antibodiesAntitumour immune responseDurable clinical benefitImmune-based therapiesT cell infiltrationCancer-immunity cycleImmune-based treatmentsTreatment of patientsMost renal cell carcinomasTumor CD8Most patientsImmune checkpointsPD-1Innovative immunotherapiesTherapeutic vaccinesWorse prognosisClinical benefit